Fluoxetine for Motor, Aphasia, and Neglect Recovery After Ischemic Stroke (FLAN)
Primary Purpose
Stroke
Status
Withdrawn
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
fluoxetine
placebo
Sponsored by
About this trial
This is an interventional treatment trial for Stroke focused on measuring stroke, recovery, fluoxetine, aphasia, neglect, motor
Eligibility Criteria
Inclusion Criteria:
- Ischemic infarction within 15 days
- Admission NIHSS item 5 score equal to or >2 -Able to give informed consent, with surrogate consent acceptable-
Exclusion Criteria:
- Pre-stroke modified Rankin Scale score equal or .3
- Pregnant or lactating
- Taking an SSRI on admission to SRH
- Taking a medication likely to have adverse interaction with an SSRI
- Unable to return for follow-up testing days 90,180
- Concurrent medial condition likely to worsen patient's functional status over next 6 months
- Unable to competently participate in testing for 45min-2hrs with rest breaks
- for MRI substudy: contraindication to MRI
Sites / Locations
- Spaulding Rehabilitation Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Fluoxetine
placebo
Arm Description
Subjects will take 20 mg fluoxetine daily for 90 days after stroke
Subjects will take one pill daily for 90 days after stroke.
Outcomes
Primary Outcome Measures
Fugl-Meyer Motor Scale (FMMS)
change in FMMS score
Fugl-Meyer Motor Scale (FMMS)
change in FMMS
Secondary Outcome Measures
Western Aphasia Battery
change in Western Aphasia Quotient
Behavioral Inattention Test (BIT)
change in BIT
Behavioral Inattention Test (BIT)
change in BIT
Functional Independence Measure
change in FIM
Fatigue Severity Scale
Beck Depression Inventory
Western Aphasia Battery
change in Western Aphasia Quotient
Beck Depression Inventory
Fatigue Severity Scale
modified Rankin Scale
modified Rankin Scale
Full Information
NCT ID
NCT01674868
First Posted
August 24, 2012
Last Updated
June 14, 2015
Sponsor
Spaulding Rehabilitation Hospital
1. Study Identification
Unique Protocol Identification Number
NCT01674868
Brief Title
Fluoxetine for Motor, Aphasia, and Neglect Recovery After Ischemic Stroke
Acronym
FLAN
Official Title
Pilot RCT of Fluoxetine vs Placebo to Treat Motor, Language and Unilateral Neglect After Ischemic Stroke
Study Type
Interventional
2. Study Status
Record Verification Date
June 2015
Overall Recruitment Status
Withdrawn
Why Stopped
unable to find patients meeting inclusion/exclusion criteria
Study Start Date
April 2013 (undefined)
Primary Completion Date
December 2015 (Anticipated)
Study Completion Date
December 2015 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Spaulding Rehabilitation Hospital
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This pilot study will recruit 25 subjects to assess the feasibility of replicating the FLAME study (Chollet, et al. Lancet 2011), a randomized controlled trial (RCT) that assessed the effect of fluoxetine vs placebo on motor recovery after ischemic stroke, in an American sample of post-acute stroke patients. This trial will in addition examine the effect of treatment with fluoxetine versus placebo on concurrent deficits in language and hemispatial attention, as well as post-stroke fatigue and will evaluate the durability of observed effects. The results of this pilot trial will be used to develop power estimates for a larger trial and to evaluate recruitment and intervention completion rates for subjects in an American post-acute environment. There are two additional substudies: the first will use MRI to assess structural changes at the beginning and end of the intervention; the second will examine the relationship of serum biomarkers of inflammation to the intervention.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Stroke
Keywords
stroke, recovery, fluoxetine, aphasia, neglect, motor
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Fluoxetine
Arm Type
Experimental
Arm Description
Subjects will take 20 mg fluoxetine daily for 90 days after stroke
Arm Title
placebo
Arm Type
Placebo Comparator
Arm Description
Subjects will take one pill daily for 90 days after stroke.
Intervention Type
Drug
Intervention Name(s)
fluoxetine
Intervention Description
20 mg daily for 90 days starting day 5-10 after stroke.
Intervention Type
Drug
Intervention Name(s)
placebo
Intervention Description
subjects will take one pill po daily for 90 days.
Primary Outcome Measure Information:
Title
Fugl-Meyer Motor Scale (FMMS)
Description
change in FMMS score
Time Frame
baseline to 90 days
Title
Fugl-Meyer Motor Scale (FMMS)
Description
change in FMMS
Time Frame
baseline to 180 days
Secondary Outcome Measure Information:
Title
Western Aphasia Battery
Description
change in Western Aphasia Quotient
Time Frame
baseline to 90 days
Title
Behavioral Inattention Test (BIT)
Description
change in BIT
Time Frame
baseline to 90 days
Title
Behavioral Inattention Test (BIT)
Description
change in BIT
Time Frame
baseline to 180 days
Title
Functional Independence Measure
Description
change in FIM
Time Frame
baseline to discharge
Title
Fatigue Severity Scale
Time Frame
baseline to 90 days
Title
Beck Depression Inventory
Time Frame
baseline to 90 days
Title
Western Aphasia Battery
Description
change in Western Aphasia Quotient
Time Frame
baseline to 180 days
Title
Beck Depression Inventory
Time Frame
baseline to 180 days
Title
Fatigue Severity Scale
Time Frame
baseline to 180 days
Title
modified Rankin Scale
Time Frame
baseline to 90 days
Title
modified Rankin Scale
Time Frame
baseline to 180 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Ischemic infarction within 15 days
Admission NIHSS item 5 score equal to or >2 -Able to give informed consent, with surrogate consent acceptable-
Exclusion Criteria:
Pre-stroke modified Rankin Scale score equal or .3
Pregnant or lactating
Taking an SSRI on admission to SRH
Taking a medication likely to have adverse interaction with an SSRI
Unable to return for follow-up testing days 90,180
Concurrent medial condition likely to worsen patient's functional status over next 6 months
Unable to competently participate in testing for 45min-2hrs with rest breaks
for MRI substudy: contraindication to MRI
Facility Information:
Facility Name
Spaulding Rehabilitation Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Fluoxetine for Motor, Aphasia, and Neglect Recovery After Ischemic Stroke
We'll reach out to this number within 24 hrs